Precancerous condition

Precancerous condition, also called premalignant condition or precursor lesion, is an umbrella term for a tissue abnormality that carries an increased probability of progressing to invasive cancer, and it is a classification concept rather than a single disease.

The category covers dysplasia, metaplasia, certain benign neoplasms and carcinoma in situ, most of which never become malignant, so the clinical task is risk stratification and surveillance rather than treating every lesion as an early cancer.

Terminology and classification

• The English terms precancerous condition, premalignant condition and precursor lesion overlap, and modern pathology increasingly prefers precursor lesion because it avoids implying that malignant transformation is inevitable.
• WHO classification of tumours uses a two-tier or three-tier grading of precursor lesions for most organs, distinguishing low-grade from high-grade intraepithelial neoplasia according to architectural and cytological atypia.
• ICD-10 has no single code for the concept and instead places carcinoma in situ in the D00 to D09 block, while dysplastic but non-in situ lesions are coded with the relevant organ or morphology code.
• ICD-11 release 2025-01 mirrors this structure with the 2E60 to 2E6Z block for in situ neoplasms, and this block is related to but not equivalent to the precancerous concept.
• Interoperability identifiers for the generic concept are MONDO:0021074, MeSH D011230, NCIT:C3341, MedGen 19442 and UMLS C0032927, and these describe a group rather than a single disease entity.
• Representative members are oral leukoplakia, Barrett's oesophagus with intestinal metaplasia, colorectal adenoma, cervical intraepithelial neoplasia, actinic keratosis, dysplastic naevus and the hereditary conditions xeroderma pigmentosum and familial adenomatous polyposis.

History

• Rudolf Virchow described metaplasia in the 1850s, establishing that one differentiated tissue could be replaced by another and providing the first mechanistic idea of a precursor state.
• Histological grading of epithelial abnormalities was systematised in the 1920s by Broders, whose grades of differentiation became the template for later dysplasia grading.
• In 1953 Slaughter, Southwick and Meznik introduced the concept of field cancerization after finding abnormal epithelium far from oral cancers, which reframed precancer as a regional rather than a focal problem.
• The term dysplasia entered cervical pathology in the 1950s, when Reagan and colleagues applied it to abnormal but non-invasive epithelium, and it was later replaced for screening purposes by the Bethesda system.
• Harald zur Hausen cloned HPV16 in 1983 and HPV18 in 1984 and received the Nobel Prize in 2008, which established that a viral infection could create a definable precancerous state.
• The first prophylactic HPV vaccine was licensed in 2006, WHO published comprehensive cervical cancer control guidance in 2014 and launched the 90-70-90 elimination strategy in 2020, which moved prevention upstream of precancer.

Epidemiology

• The frequency of precancerous conditions depends entirely on which entity is counted, so statements must name the lesion, the population and the detection method.
• Colorectal adenomas are found in 30 to 50 per cent of adults over 50 years who undergo screening colonoscopy, and prevalence rises with age and with male sex.
• Actinic keratosis affects 10 to 20 per cent of fair-skinned adults in sunny climates, and its prevalence increases with cumulative ultraviolet exposure and immunosuppression after transplantation.
• Oral leukoplakia has a global prevalence of about 1 to 5 per cent, and reported malignant transformation rates range from 3 to 17 per cent, with the highest risk in non-homogeneous lesions.
• Untreated cervical intraepithelial neoplasia grade 3 carries an approximately 30 per cent risk of invasive cancer over 30 years, a figure derived from the 2008 McCredie follow-up of New Zealand women.
• Barrett's oesophagus progresses to oesophageal adenocarcinoma at about 0.1 to 0.3 per cent per patient-year, and low-grade dysplasia roughly triples that annual risk.
• Named risk factors are high-risk HPV types 16 and 18, which cause about 70 per cent of cervical cancers, tobacco and alcohol for oral lesions, ultraviolet light for skin lesions, obesity and reflux for Barrett's, and APC or mismatch repair mutations for inherited polyposis.
• The global context is set by GLOBOCAN 2020, which estimated 19.3 million new cancer cases and 10 million deaths, and IARC attributes a substantial share to infections and to preventable exposures that also cause precursor lesions.

Pathophysiology

• Precancerous lesions arise through the stepwise accumulation of genetic and epigenetic alterations, and the colorectal adenoma-to-carcinoma sequence described by Fearon and Vogelstein in 1990 remains the best known model.
• The sequence typically involves loss of the tumour suppressor APC, activating mutation of KRAS, loss of TP53 and additional changes in chromatin regulation and DNA repair.
• Dysplasia is defined by architectural disorder and cytological atypia, including nuclear enlargement, hyperchromasia, pleomorphism and increased mitotic figures, and grading reflects the proportion of the epithelium involved.
• Metaplasia such as Barrett's intestinal metaplasia replaces one differentiated epithelium with another that is better able to survive chronic injury, and the new epithelium carries a higher risk of further mutation.
• Field cancerization explains why multifocal lesions and local recurrence arise after complete excision, because the surrounding epithelium already carries shared mutations and epigenetic changes.
• Viral oncogenesis illustrates a definable precursor state: HPV E6 and E7 proteins inactivate p53 and retinoblastoma protein, and the resulting dysplastic clone accumulates further alterations before invasion.

Clinical features

• Most precancerous conditions are asymptomatic and are found by screening, by incidental biopsy or by surveillance of a patient with a previous lesion.
• Site-specific signs include a white oral patch in leukoplakia, a rough scaly macule in actinic keratosis, a changing pigmented naevus, a velvety red patch in erythroplakia and reflux symptoms in Barrett's oesophagus.
• Bleeding, ulceration, induration, rapid growth, pain or a newly palpable mass in a known precursor lesion are red flags for invasive transformation and require urgent biopsy.
• Named complications are progression to invasive cancer, local recurrence after incomplete excision, overtreatment with functional loss such as cervical incompetence after conisation, and substantial anxiety related to the cancer label.
• Special populations are immunocompromised patients, in whom HPV-driven lesions progress faster, transplant recipients with cutaneous dysplasia, and patients with xeroderma pigmentosum or familial adenomatous polyposis who develop many lesions early.
• Prognosis depends on the entity and grade, since low-grade lesions regress in a substantial proportion whereas high-grade lesions have a much higher and more predictable rate of progression.

Diagnosis

• Histopathology is the gold standard, and every precursor diagnosis should be reported with the entity name, the grade and the adequacy of the excision margins.
• Tissue is obtained by punch or incisional biopsy for skin and oral lesions, by endoscopy with targeted biopsy for gastrointestinal lesions and by colposcopy-directed biopsy or conisation for cervical lesions.
• Screening programmes are designed to detect precursors before invasion and include cervical cytology with HPV testing, colonoscopy after a positive faecal immunochemical test, skin examination in high-risk patients and oral examination in tobacco users.
• Adjunctive tests include p16 and Ki-67 dual staining for cervical lesions, methylated DNA markers in stool or blood, Lugol's iodine and chromoendoscopy for oesophageal lesions, and dermoscopy for pigmented skin lesions.
• Terminology in reports follows the WHO classification for each organ and the Bethesda system for cervical cytology, and the Paris classification for superficial gastrointestinal lesions, so that grades are comparable between centres.
• The differential diagnosis includes reactive or inflammatory atypia, benign hyperplasia, in situ carcinoma, early invasive carcinoma and, for pigmented lesions, benign naevi and melanoma.
• Overdiagnosis is a recognised problem because screening detects lesions that would never have caused symptoms, and the balance between detection and harm is the central quality issue of every precursor screening programme.

Management

• Management is risk-stratified: low-grade lesions with a low progression rate are usually surveilled, whereas high-grade lesions are treated because the risk of invasion is substantial.
• Excisional techniques include endoscopic mucosal resection and submucosal dissection for gastrointestinal lesions, large loop excision of the transformation zone or conisation for cervical lesions, and wide local or Mohs excision for skin lesions.
• Ablative and topical options include cryotherapy, laser ablation, topical 5-fluorouracil and imiquimod for actinic keratosis, and photodynamic therapy for field change in sun-damaged skin.
• Chemoprevention has a defined but narrow role: celecoxib reduces adenoma burden in familial adenomatous polyposis, and HPV vaccination prevents the precursor lesions that precede most cervical cancers.
• Primary prevention addresses shared causes: smoking cessation and alcohol reduction for oral and oesophageal lesions, sun protection and sunscreen for skin lesions, weight control and reflux management for Barrett's, and vaccination before sexual exposure for HPV.
• Surveillance intervals follow named guidelines such as the 2020 US Multi-Society Task Force recommendations for post-polypectomy colonoscopy and the WHO 2020 cervical screening guidance, and intervals lengthen or shorten according to baseline findings.
• After treatment, the excised specimen determines follow-up, because an incomplete margin or a higher grade than suspected at biopsy changes the interval and sometimes the need for further excision.
• Prognosis is excellent when a precursor is treated before invasion, and the five-year survival of true in situ disease approaches that of the general population for most organs.

Research and controversies

• Molecular biomarkers such as DNA methylation panels, p16/Ki-67 dual stain and circulating tumour DNA are being evaluated to decide which low-grade lesions will progress, so that surveillance can be targeted.
• Artificial intelligence is being tested for histological grading and for optical diagnosis during endoscopy, but the effect on cancer incidence rather than on detection rate has not been demonstrated.
• The boundary between a precursor and an early cancer is contested for several organs, and the resulting stage migration changes treatment radically without necessarily changing outcome.
• Chemoprevention trials with celecoxib, aspirin and metformin have shown modest effects, and none has been adopted as a population strategy because benefit is small and toxicity is real.
• The terminology itself remains contested, and a 2018 international consensus proposed replacing dysplasia with a unified intraepithelial neoplasia vocabulary so that pathologists, surgeons and patients describe the same risk.